-
-
-
-
-
-
-
Raymond James Downgrades Apellis Pharmaceuticals (APLS) to Market Perform
-
-
-
-
-
-
-
Apellis Pharmaceuticals (APLS) PT Raised to $41 at Barclays
-
-
-
-
-
-
-
Apellis Pharmaceuticals (APLS) PT Lowered to $31 at Cantor Fitzgerald
-
-
-
-
-
-
-
BofA Securities Upgrades Apellis Pharmaceuticals (APLS) to Buy
-
-
-
-
-
-
-
Apellis Pharmaceuticals (APLS) PT Lowered to $48 at Stifel - Aims to Grow in 2026
-
-
-
-
-
-
-
Apellis Pharmaceuticals (APLS) PT Raised to $22 at RBC Capital
-
-
-
-
-
-
-
Apellis Pharmaceuticals (APLS) PT Raised to $21 at Mizuho
-
408,905 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

